A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders
Unlike most peptides, BPC-157 is remarkably stable in an acidic gastric environment (pH 1-2) for more than 24 hours, making it a candidate for oral administration in research
Safety evaluation of a novel muramidase for feed application
Another potential immunomodulatory effect involves microbial diversity in two studies (20, 21): Low gut microbial diversity is associated with metabolic disease (42), and high diversity may be due to the high expression of SIRT1 and high levels of HDL (20) and improve body immune system, such as liver function mentioned in the study by Li et al
539 Results from several Phase III clinical trials (ORION-9/10/11, NCT03397121, NCT03399370, and NCT03400800) have shown that subcutaneous injections of inclisiran every 6 months considerably reduce LDL-C levels by 4852%, demonstrating sustained efficacy and good tolerability
Factors such as potency, additional ingredients, and formulation affect their efficacy
